Last update 24 Apr 2025

ABN202

Overview

Basic Info

Drug Type
Antibody fusion proteins
Synonyms
ABN 202, ABN-202, ABN202
Target
CLDN3 x EGFR x IFNβ x Trop-2
Action
inhibitors, antagonists, stimulants
Mechanism
CLDN3 inhibitors(claudin 3 inhibitors), EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), IFNβ stimulants(Interferon beta stimulants)
Therapeutic Areas
NeoplasmsDigestive System DisordersRespiratory Diseases+ [2]
Active Indication
Colorectal CancerNon-Small Cell Lung CancerBiliary Tract Neoplasms+ [2]
Inactive Indication-
Originator Organization
ABION, Inc.ABION, Inc.Genopharm Co. Ltd.Genopharm Co. Ltd.Startup
Active Organization
ABION, Inc.ABION, Inc.Genopharm Co. Ltd.Genopharm Co. Ltd.StartupSeoul National UniversitySeoul National University
Inactive Organization-
Drug Highest PhasePreclinical
First Approval Date-
Regulation-

Related

100 Clinical Results associated with ABN202
Login to view more data
100 Translational Medicine associated with ABN202
Login to view more data
100 Patents (Medical) associated with ABN202
Login to view more data
100 Deals associated with ABN202
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Colorectal CancerPreclinical
South Korea
ABION, Inc.ABION, Inc.
29 Apr 2025
Colorectal CancerPreclinical
South Korea
Seoul National UniversitySeoul National University
29 Apr 2025
Non-Small Cell Lung CancerPreclinical
South Korea
ABION, Inc.ABION, Inc.
23 Aug 2024
Biliary Tract NeoplasmsPreclinical
South Korea
Genopharm Co. Ltd.Genopharm Co. Ltd.Startup
09 Apr 2024
Biliary Tract NeoplasmsPreclinical
South Korea
ABION, Inc.ABION, Inc.
09 Apr 2024
Triple Negative Breast CancerPreclinical
South Korea
Genopharm Co. Ltd.Genopharm Co. Ltd.Startup
09 Apr 2024
Triple Negative Breast CancerPreclinical
South Korea
ABION, Inc.ABION, Inc.
09 Apr 2024
Bladder CancerPreclinical
South Korea
ABION, Inc.ABION, Inc.
22 Mar 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free